

## India Update

### Contents

Page 2	<b>Sun Pharmaceutical (Rs1,656):</b> Slowly emerging from shadows	<b>Hold</b>
Page 3	<b>Union Bank of India (Rs260):</b> Margin accretion on the cards	<b>Buy</b>
Page 4	<b>Zee News (Rs63):</b> Money on the table	<b>Buy</b>
Page 5	<b>Recent reports/updates</b>	

### Highlights


Sector/event	Impact
<b>PHARMA:</b> <b>Sun Pharmaceutical (SPIL) – Company update</b>	SPIL launched generic <i>Eloxatin</i> injections in the US after about seven months of receiving the US FDA approval. This is positive given that SPIL will be one of the five players in the market and could potentially generate an additional EPS of Rs6-7, which was excluded in our estimates. Factoring in the upside, we raise FY10E & FY11E EPS 2% & 9% and increase target price to Rs1,583 from Rs1,308. Besides, with the US FDA recently rejecting citizen's petition by Osmotica Pharma, all hurdles seem to be surmounted and SPIL hopes for an approval for the generic tablet version of <i>EffexorXR</i> capsules, implying an additional EPS of Rs4-6. However, we still maintain HOLD on SPIL given high valuations, huge idle cash and uncertainties over takeover battle for Taro & ongoing US FDA issues.

### News Snippets


#### Corporate

- State Bank of India plans to invest Rs5-10bn in the general insurance business in synergy with Insurance Australia Group, with the former keeping 74% and the latter 24%. The entity would be named as the SBI General Insurance. (Business Standard)
- The Uttarakhand Government is setting up two gas-based plants of 500MW each in collaboration with Gas Authority of India. (Business Standard)
- Fortis Healthcare's Singapore-based hospital chain Parkway will be funded by short-term loans estimated at ~Rs25bn, to be raised from a host of banks and financial institutions. (The Economic Times)
- Vedanta Resources is likely to demerge a large aluminium project in Orissa into a separate entity to help the conglomerate get a better valuation for the aluminium business. (The Economic Times)
- Reliance Industries and US-based sports marketing company, IMG Worldwide have joined hands to build a professional sports business in India. The equal joint venture between the two would also manage entertainment businesses. (Business Standard)


Market movement over last fortnight



Volumes in Rs mn (BSE and NSE)



Advances & Declines ratio (BSE)



ICICI Securities Limited, ICICI Centre, H.T. Parekh Marg, Churchgate, Mumbai – 400 020, India.

Phone: +91 22 2288 2460/70 Fax: +91 22 2288 2448

ICICI Securities Inc, 461 Fifth Avenue, 16<sup>th</sup> Floor, New York, NY 10017.

Phone: +1 212 921 2344 / +1 212 453 6704 Fax: +1 212 453 6710

#### Market data as on Mar 12, 2010

INDICES			% chg (DoD)
BSE Sensex	17167		(0.01)
S&P CNX Nifty	5137		0.07
BSE 100	9116		(0.03)
BSE 200	2157		(0.06)

#### OVERSEAS MARKETS

		% chg (DoD)
Dow Jones	10625	0.12
Nasdaq Comp.	2368	(0.03)
S&P 500	1150	(0.02)
Hang Seng	21030	(0.85)
Nikkei	10733	(0.17)

#### ADVANCES/DECLINES (BSE)

Group	A	B	S
Advances	69	666	145
Declines	127	1211	296
Unchanged	2	57	9

#### FII TURNOVER (BSE+NSE)\* (Rs mn)

Bought	Sold	Net
23030	18560	4470

#### NEW HIGHS AND LOWS (BSE)

Group	A	B	S
High	3	53	7
Low	0	17	2

#### CURRENCY

US\$1 = Rs45.44

\* FII turnover (BSE + NSE) as on March 11, 2010

## Sun Pharmaceutical Industries (Hold)

## PHARMA

## COMPANY UPDATE

## Slowly emerging from shadows

Rs1,656

Rajesh Vora (+91 22 6637 7508)

rajesh.vora@icicisecurities.com

## Target price Rs1,583

## Earnings revision

(%)	FY10E	FY11E
Sales	↑ 0.9	↑ 4.1
EBITDA	↑ 1.7	↑ 8.6
EPS	↑ 1.9	↑ 8.9

## Target price revision

Rs1,583 from Rs1,308

Sun Pharmaceutical Industries (SPIL) launched generic *Eloxatin* injections in the US after about seven months of receiving the US FDA approval. This is positive given that SPIL will be one of the five players in the market and could potentially generate an additional EPS of Rs6-7, which was excluded in our estimates. Factoring in the upside, we raise FY10E & FY11E EPS 2% & 9% and increase target price to Rs1,583 from Rs1,308. Besides, with the US FDA recently rejecting citizen's petition (CP) by Osmotica Pharma, all hurdles seem to be surmounted and SPIL hopes for an approval for the generic tablet version of *EffexorXR* capsules, implying an additional EPS of Rs4-6. However, we still maintain HOLD on SPIL given high valuations, huge idle cash and uncertainties over takeover battle for Taro & ongoing US FDA issues.

## Table 1: Valuations summary

		Y/E March	EPS (Rs)	P/E (x)	EV/E (x)		
Price (12/3/10) (Rs)	1,656	2009	87.7	18.9	17.6	M.Cap. (Rs bn)	343.3
52 wk Range (Rs)	1,693/993	2010E	58.3	28.4	23.6	M.Cap (US\$ bn)	7.5
Dividend yield 2010E (%)	0.7	2011E	68.1	24.3	22.2	Shares Out (mn)	207.3
BSE Sensex	17167	2012E	78.3	21.1	18.9	Free Float (%)	36.3

Source: Company data, I-Sec Research

- **Upside from generic *Eloxatin* priced in; approval for *EffexorXR* awaited.** Based on our quick estimates for generic *Eloxatin*, SPIL could generate ~US\$30mn profits and Rs6-7 EPS given a five-player scenario – Teva & Hospira are well-entrenched and Sandoz & Fresenius Kabi Pharma launching on March 10. Ascribing 5x P/E to Rs6-7 EPS upside from the drug, the upside could be worth Rs30-35/share -- SPIL already gained net Rs15/share in the last two days. Besides, the stock is up ~12% since Q3FY10 earnings call on January 30, largely in anticipation of the likely launch of the generic tablet version of *EffexorXR* capsules. But the actual launch could have further positive impact on the stock price and sentiment.
- **Earnings post *Protonix* launch & outcome of US FDA issues and Taro takeover hold the key.** Generic *Protonix* forms an estimated 15-20% of SPIL's net profits, which will shrink after January '11, when the last patent expires (including paediatric exclusivity). Also, uncertainty on the Taro takeover, ongoing US FDA issues pertaining to Caraco's Detroit facility and rising level of surplus cash (~Rs35bn now likely to rise to ~Rs45bn by end-FY12E) are key concerns.
- **SPIL appears fully valued; maintain HOLD.** While, in our view, Caraco is a deep-value BUY given the likely resolution of the warning letter by US FDA (by end-'10), SPIL seems fully valued bearing in mind FY11E P/E of 24x (five-year average 18x) and potential earnings volatility due to first-to-files (FTFs) & likely dip in profits from generic *Protonix*.

Details in our report '*Slowly emerging from shadows*' dated March 12, 2010

## Union Bank of India (Buy)

## BANKING

## MANAGEMENT MEET

## Margin accretion on the cards

Rs260

Siddharth Teli (+91 22 6637 7298)  
Abhishek Murarka (+91 22 6637 7351)

siddharth.teli@icicisecurities.com  
abhishek.murarka@icicisecurities.com

Target price Rs315

Target price revision

Rs315 from Rs287

Our recent meeting with Union Bank of India (UBI) reaffirms our positive stance on the bank – we expect strong NIM traction to continue and fee income growth to remain robust. Loan growth is likely to surprise on the upside, which will lead to higher loan/deposit ratios and hence, margin accretion. While short-term asset quality issues persist, they are manageable in our view. UBI is well poised to deliver +22% RoE in FY11E. While the stock has underperformed its peers in the past few months, we believe it offers significant upside from the current levels given UBI's superior return ratios among peers. We reiterate BUY with a revised target price of Rs315/share.

Table 1: Valuations summary

		Y/E March	EPS (Rs)	P/E (x)	P/BV (x)		
Price (12/3/10) (Rs)	260	2009	34.2	7.6	1.9	M.Cap. (Rs bn)	131.3
52 wk Range (Rs)	284/125	2010E	39.2	6.6	1.5	M.Cap (US\$ bn)	2.8
Dividend yield 2010E (%)	2.3	2011E	44.6	5.8	1.2	Shares Out (mn)	505.1
BSE Sensex	17167	2012E	52.7	4.9	1.0	Free Float (%)	44.6

Source: Company data, I-Sec Research

- **NIM traction to continue led by rising loan-to-deposit.** We expect loan/deposit ratios to continue improving as the management targets +23% loan growth in FY11 (I-Sec 21%), leading to sharp NIM improvement. As per the management, Q4FY10 NIMs are at ~3% (much higher than 2.74% in Q3FY10 & 2.4% in 9MFY10). We have factored in 13bps YoY margin expansion in FY11E and believe that there could be some upside to our estimates.
- **Fee income growth to remain robust; costs under control.** The management remains confident of maintaining traction in fee income given expectations of a sharp revival in credit growth in FY11 and considering that chunk of fee income is credit linked. While fee income growth guidance is at +25%, we have factored in 19% growth in other income (ex-treasury) in FY11E. Despite UBI mulling to expand to 300 branches in FY11 (~300 branches in FY10E), we believe cost-to-income will remain at ~40% and cost-to-assets at ~1.4%.
- **Short-term asset quality issues persist but manageable.** We note that delinquencies have been rising in the past few quarters and were at 2.03% as of Q3FY10. We expect performance of restructured book to be in line with PSU peers. NPAs from this book will likely peak at ~10% by December '10. We assume a slippages ratio of 1.9% in FY10E with GNPA's higher than management expectations. The management also indicated that with 10-year G-Sec yields at 8%, the bank would take a hit of Rs11-12mn per basis point (base yield of 7.59% as on Q3FY10).
- **Superior return ratios; reiterate BUY.** Despite short-term asset quality issues, we believe that UBI will maintain its above-industry return ratios with RoA and RoE at 1.1% and 23% respectively through FY12E. Strong core operating performance driven by NIM expansion will likely rectify the recent underperformance. Short-term deterioration in asset quality is not expected to be alarming. We reiterate BUY with a target price of Rs315/share (1.5x FY11 BV). Slower-than-expected NIM expansion and higher-than-expected slippages are key risks.

Details to follow in our report '*Margin accretion on the cards*' dated March 15, 2010

## Zee News (Buy)

## MEDIA

## COMPANY UPDATE

## Money on the table

Rs63

Vikash Mantri, CFA (+91 22 6637 7161)  
Satish Kothari (+91 22 6637 7510)

vikash.mantri@icicisecurities.com  
satish.kothari@icicisecurities.com

## Target price Rs71

The Street is valuing Zee News's (ZNL) residual news business currently at Rs3.1/share post the announcement of the demerger of regional general entertainment channels (R-GECs) with Zee Entertainment Enterprises (ZEEL) – this implies ~Rs750mn market value and Rs1,550mn EV for ZNL's residual news business after factoring in Rs800mn debt. ZNL's residual news business is trading at an attractive FY11E EV/EBITDA & EV/sales of 5.3x & 0.55x respectively. The current implied value of ZNL's R-GECs is Rs58/ZNL share based on ZEEL's market price of Rs278/share. We believe ZNL is better placed versus competitors as it generates higher revenues (~Rs700mn) from subscription due to a legacy agreement with Zee Turner. We value ZNL's residual news business at Rs3bn or Rs13/share based on 1.5x FY10E EV/sales. In our view, there is a high probability that the R-GEC demerger with ZEEL will go through and based on guidance, we expect it to be over by FY10. We maintain BUY on ZNL with Rs71 target price – Rs58/share from R-GECs (as per the announced swap ratio) & Rs13/share from the residual news business – implying 14% upside from the current levels.

Table 1: Valuations summary

		Y/E March	EPS (Rs)	P/E (x)	EV/E (x)		
Price (12/3/10) (Rs)	63	2009	1.9	33.6	19.9	M.Cap. (Rs bn)	15.1
52 wk Range (Rs)	65/29	2010E	2.4	25.6	14.1	M.Cap (US\$ mn)	325
Dividend yield 2010E (%)	1.2	2011E	3.1	20.5	11.2	Shares Out (mn)	239.8
BSE Sensex	17168	2012E	3.6	17.2	9.6	Free Float (%)	45.9

Source: Company data, I-Sec Research

- **ZNL – Valuations attractive.** Post the restructuring, ZNL's residual business will be comparable with TV Today (TVTN), the leader in the Hindi news genre with flagship channel, *Aaj Tak*. We value ZNL's residual business at 1.5x FY10E EV/sales or Rs13/share (TVTN 1.9x).
- **Hindi news channels improving share.** ZNL's flagship Hindi news channel increased its market share to ~13% in January '10 from ~11% in July '09; it is the #4 player in the Hindi space. ZNL has been able to garner premium rates owing to its brand pull and strong traction among male 25+ metro centric target group.
- **Strong business model.** ZNL garners ~Rs700mn revenues from subscription due to a legacy arrangement with Zee Turner – For ZNL, subscription revenues formed 17.5% of total revenues in 9MFY10, whereas other news channels struggled to even generate 10% from subscription. This protects ZNL from the vagaries of the ad market and assists in delivering better profitability than other news companies. We expect ZNL's residual business to post Rs2.8bn revenues & Rs290mn EBITDA in FY11E. At present, profitability is subdued due to losses in Telugu & Tamil news channels launched recently. Profits are likely to improve over time as losses reduce.

Details in our report '*Money on the table*' dated March 12, 2010

Recent reports/updates		
Analyst	Company/Sector	Date
Rajesh Vora	Sun Pharmaceuticals: Slowly emerging from shadows	Mar 12
Vikash / Satish	Zee News: Money on the table	Mar 12
Anantha/I-Sec Research	India Unlimited: Ninth Annual Investor Conference 2010	Mar 10
Gaurav / Shaleen	Mundra Port: Dear valuations outweigh core story	Mar 8
Vikash / Satish	Media Monitor: Ad spends – From cautious to clear optimism	Mar 8
Amit / Gagan	Gujarat Gas: LNG saves the day	Mar 8
Abhijit Mitra	Steel sector: In winsome weather	Mar 5
Abhijit Mitra	SAIL: Poised to outperform	Mar 5
Abhijit Mitra	JSWS: Steering clear of troubled waters	Mar 5
Abhijit Mitra	Tata Steel: Cold spell	Mar 5
Abhijit Mitra	Adhunik Metaliks: Amassing affluence	Mar 5
Abhijit Mitra	Usha Martin: Robust Q4 to set the tone	Mar 5
Gaurav / Shaleen	Marg: Well anchored	Mar 5
Rajesh Vora	Ranbaxy Laboratories: Smart manoeuvre	Mar 3
Prakash / Sanket	Tata Power: Not as bad as it appeared	Mar 3
Krupal / Varun	Ambuja Cement: Bastion of strength	Mar 3
Sanjay / Pratik	ITC: Taxation hiccups	Mar 3
I-Sec Equity Research	Union Budget 2010: On a sound footing	Feb 26
Rajesh Vora	Ranbaxy Laboratories: FTF harvesting begins	Feb 26
Sandeep / Krupal / Varun	Mphasis: Increasing earnings risk	Feb 26
Amit / Gagan	Oil&Gas Sector: BPCL better placed than HPCL	Feb 25
Rajesh Vora	Aventis Pharma: Disappointing show	Feb 25
Krupal Maniar	Shree Cement: De-risked model	Feb 23
Vikash / Satish	Bharti Airtel: African safari gamble worth it	Feb 22
Sanjay / Pratik	Nestle: One-off costs pinch profits	Feb 22
Abhijit Mitra	Tata Steel: Pension, the last prop?	Feb 19
Rajesh Vora	GSK Pharma: Captain at the fore	Feb 19
Amit / Gagan	BPCL: Possible KG-D6 size discovery in Mozambique	Feb 19
Sandeep / Krupal	Hexaware Technologies: Higher-than-anticipated pain	Feb 18
Amit / Gagan	Indraprastha Gas: Onset of a bright future	Feb 18
Abhijit Mitra	Hindalco: Peaked profitability	Feb 17
Vikash / Satish	Subscriber Watch: Uninor maintains steam	Feb 17
Rajesh Vora	GSK Pharma: Decent show	Feb 16
Rajesh Vora	Pharma Theme: Destiny's favoured child	Feb 15
Sandeep / Krupal	Patni Computer Systems: Margins enthrall	Feb 15
Siddharth / Abhishek	Banking sector: RBI proposal for loan pricing	Feb 11
Abhijit Mitra	Usha Martin: Robust Q4 to set the tone	Feb 9
Vikash / Satish	Media Monitor (February '10): Q3FY10 review – Earnings ...	Feb 8
Hemant Joshi	Tata Motors: Bolstering up	Feb 5
Krupal / Navneet	Ambuja Cement: Better poised	Feb 4
Krupal / Navneet	ACC: Margin blues	Feb 4
Abhijit Mitra	Adhunik Metaliks: Amassing affluence	Feb 4
Anantha / Pratik	Market Earnings Review (OND-09) – Broad trend, as expected	Feb 4
Prakash / Sanket	Fertiliser sector: P&K fertiliser – Many challenges ahead ...	Feb 3
Sanjay / Pratik	P&G Hygiene: In good health	Feb 2
Vikash / Satish	MTNL: Pension pains	Feb 2

*I-Sec investment ratings (all ratings relative to Sensex over next 12 months)*

**BUY:** +10% outperformance; **HOLD:** -10% to +10% relative performance; **SELL:** +10% underperformance

#### ANALYST CERTIFICATION

We I/, *Rajesh Vora, Grad. CWA, CFA; Siddharth Teli, MBA (Finance); Abhishek Murarka, PGDM, MBA (Finance); Vikash Mantri, PGDM, CFA and Satish Kothari, PGDM*; research analyst and the author of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of ICICI Securities Inc.

#### Disclosures:

ICICI Securities Limited (ICICI Securities) and its affiliates are a full-service, integrated investment banking, investment management and brokerage and financing group. We along with affiliates are leading underwriter of securities and participate in virtually all securities trading markets in India. We and our affiliates have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. Our research professionals provide important input into our investment banking and other business selection processes. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their dependent family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on reasonable basis, ICICI Securities, its subsidiaries and associated companies, their directors and employees ("ICICI Securities and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Nonrated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities is acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgement by any recipient. The recipient should independently evaluate the investment risks. The value and return of investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities and affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities and its affiliates might have managed or co-managed a public offering for the subject company in the preceding twelve months. ICICI Securities and affiliates might have received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of public offerings, corporate finance, investment banking or other advisory services in a merger or specific transaction. ICICI Securities and affiliates expect to receive compensation from the companies mentioned in the report within a period of three months following the date of publication of the research report for services in respect of public offerings, corporate finance, investment banking or other advisory services in a merger or specific transaction. It is confirmed that *Rajesh Vora, Grad. CWA, CFA; Siddharth Teli, MBA (Finance); Abhishek Murarka, PGDM, MBA (Finance); Vikash Mantri, PGDM, CFA and Satish Kothari, PGDM*; research analyst and the author of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Our research professionals are paid in part based on the profitability of ICICI Securities, which include earnings from Investment Banking and other business.

ICICI Securities or its affiliates collectively do not own 1 or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

It is confirmed that *Rajesh Vora, Grad. CWA, CFA; Siddharth Teli, MBA (Finance); Abhishek Murarka, PGDM, MBA (Finance); Vikash Mantri, PGDM, CFA and Satish Kothari, PGDM*; research analyst and the author of this report or any of their family members does not serve as an officer, director or advisory board member of the companies mentioned in the report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. ICICI Securities and affiliates may act upon or make use of information contained in the report prior to the publication thereof. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.